Kairos Pharma Ltd. (NYSE American: KAPA) announced it has signed a term sheet for a strategic asset acquisition from Celyn Therapeutics Inc., under which it would obtain worldwide rights to two clinical-stage assets targeting non-small cell lung cancer. The proposed acquisition would expand the company’s oncology pipeline with late-preclinical and Phase 1-ready candidates designed to address EGFR mutations and MET-driven resistance mechanisms in NSCLC, a multi-billion dollar market.
The assets include CL-273, a pre-IND, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, oral type IIb c-MET kinase inhibitor. Kairos indicated that dual inhibition of EGFR and MET pathways could overcome compensatory signaling and extend progression-free survival, positioning the assets for potential monotherapy and combination development pending completion of the transaction. The company’s latest news and updates are available in its newsroom at https://ibn.fm/KAPA.
Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company’s lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.
Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer aimed at addressing significant unmet medical needs. As of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator. The full press release can be viewed at https://ibn.fm/MPrrW.
The acquisition represents a strategic move for Kairos Pharma as it seeks to strengthen its position in the competitive NSCLC treatment landscape. Non-small cell lung cancer remains a leading cause of cancer mortality worldwide, creating substantial demand for novel therapeutic approaches that can overcome resistance mechanisms and improve patient outcomes. The company’s focus on addressing both EGFR mutations and MET-driven resistance could potentially offer new treatment options for patients who have developed resistance to existing therapies.
BioMedWire, which distributed the press release, is a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers various communication solutions. For more information about BioMedWire, visit https://www.BioMedWire.com. Full terms of use and disclaimers applicable to all content provided by BMW are available at https://www.BioMedWire.com/Disclaimer.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Kairos Pharma Expands Oncology Pipeline with Acquisition of Two Clinical-Stage NSCLC Assets.